Skip to content
Share

|

eAlerts

|

Register

|

Login
  • Services
    • News Services
    • Conference Coverage & Reporting
    • Expert Interviews & Discussion
    • Featured Content Creation
    • Multimedia
  • Specialties
  • Showcase
  • Clients
  • News & Insights
  • About
  • Contact

Day: March 3, 2025

Larotrectinib discontinuation possible for some paediatric NTRK fusion-positive tumours

A cute elementary age girl with cancer is wearing a pink scarf on her head. She is at a medical appointment. The female doctor of African descent is holding the child's hands, providing comfort and support. The child is smiling at the camera.

Children who respond to larotrectinib therapy for sarcoma with a neurotrophic tyrosine receptor kinase gene fusion may be able to discontinue treatment, indicates research published in the Journal of Clinical Oncology.

Building relationships through trusted content for healthcare professionals

GET STARTED
A global leader in medical content

© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.

Twitter Icon-social_rss
Social Share
Contact
eAlerts
Register
Login
Terms of Use
Privacy Policy
Cookie Policy